About us

Research results

Since its creation in 1996, IDIBAPS has shown a growth of the main research outcomes: scientific publications, translation of knowledge and innovation, and capacity to get research funds.

Scientific publications

The number and quality of papers published by IDIBAPS have not stopped increasing since its creation in 1996 to 2012. Since 2012 the progressions of the figures show a plateau trend.

Indicators are divided into three groups intended to reflect output (number of publications), quality (total and mean impact factor and %Q1) and intramural collaboration (% of publications carried out by one, two or more IDIBAPS teams). In 2014 these figures were as follows:

Figure title: 2014 publication outputs.
Output – Total number of documents published in scholarly journals indexed in the ISI Web of Science.
Total IF – Accumulated impact factor of all the scientific publications.
Mean IF – Mean impact factor of all the scientific publications.
%Q1 – % of publications published in journals ranked in the first quartile (top 25%) of their category as ordered by the 2013 Journal Citation Reports, ISI Web of Science (Thomson Reuters, Inc.).

Figure title: 2014 intra-mural collaboration original articles. Distribution of the original articles authored by members of one, two, three and four or more IDIBAPS teams.

Only original articles were taken into consideration. Publications resulting from collaboration between teams from two different areas have been counted once for each area, so the sum of the articles per area is higher than the total.

Only original articles were taken into consideration.

Translation of knowledge and innovation

At IDIBAPS we are focused to benefit patients and society by getting valuable products to market that without industrial partners would be unable to find the resources to reach the marketplace. At IDIBAPS we have the expertise to undertake all aspects of negotiations required when dealing with commercial organizations and can also advise on the best plan of action for anyone who is exploring the option of setting up a new company.

The Institute currently manages 51 patent families and 8 registered software, and we have signed 17 license agreements with several industry partners.

Figures in 2014:

  • 5 spin-off companies created by IDIBAPS researchers since 2006
  • 9 patent applications: 1 Spanish patent application, 1 European patent applications, 6 PCT extension applications, and 1 National phase application
  • 8 license agreements signed
  • 27 clinical guidelines published. These guidelines have a tremendous impact in patients’ care and medical practice.
  • 282 clinical trials approved by the Clinical Research Ethics Committee (CREC ).